Protocol No. | Title |
---|---|
ATRIUM-ICI-M1201 | ATRIUM-ICI-M1201: AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis |
MCC-16-MULTI-18-PMC | Genomic Testing for Patients with Refractory Cancer to Determine Treatment |
MCC-16-MULTI-19-PMC | Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies |
MCC-17-MTB-01-PMC | MCC-17-MTB-01-PMC: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
MCC-20-MULTI-34 | Tobacco Treatment Optimization and Preferences during Concurrent Cancer Treatment (TTOP) |
MCC-22-64346 | MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study) |
MCC-23-MULTI-61 | Comprehensive Connected Cancer Care (C4): Intervention Evaluation |
NCI-CIRB-A031704 | Nivolumab+Ipilimumab with Nivolumab vs. Cabozantinib+Nivolumab in Metastatic Untreated RCC |
NCI-CIRB-APEC14B1 | Project:EveryChild |
NCI-CIRB-AREN1921 | NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
NCI-CIRB-EAY191-E5-MATCH-PMC | Testing the Use of AMG 510 and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor |
NCI-CIRB-EAY191-N5-MATCH-PMC | NCI-CIRB-EAY191-N5-MATCH-PMC: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors, A ComboMATCH Treatment Trial |
Protocol No. | Title |
---|---|
ATRIUM-ICI-M1201 | ATRIUM-ICI-M1201: AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis |
MCC-16-MULTI-18-PMC | Genomic Testing for Patients with Refractory Cancer to Determine Treatment |
MCC-16-MULTI-19-PMC | Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies |
MCC-17-MTB-01-PMC | MCC-17-MTB-01-PMC: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
MCC-20-MULTI-34 | Tobacco Treatment Optimization and Preferences during Concurrent Cancer Treatment (TTOP) |
MCC-22-64346 | MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study) |
MCC-23-MULTI-61 | Comprehensive Connected Cancer Care (C4): Intervention Evaluation |
NCI-CIRB-A031704 | Nivolumab+Ipilimumab with Nivolumab vs. Cabozantinib+Nivolumab in Metastatic Untreated RCC |
NCI-CIRB-APEC14B1 | Project:EveryChild |
NCI-CIRB-AREN1921 | NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
NCI-CIRB-EAY191-E5-MATCH-PMC | Testing the Use of AMG 510 and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor |
NCI-CIRB-EAY191-N5-MATCH-PMC | NCI-CIRB-EAY191-N5-MATCH-PMC: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors, A ComboMATCH Treatment Trial |
Protocol No. | Title |
---|---|
MCC-22-64346 | MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study) |
NCI-CIRB-APEC14B1 | Project:EveryChild |
NCI-CIRB-AREN1921 | NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |